Articles tagged with Lymphoma
The study reveals three new subsets of follicular T cells that increase in follicular lymphoma, each with distinct gene expression and spatial distribution patterns. These T-cell subsets serve as a strong predictor of patient prognosis, enhancing treatment approaches for the disease.
Researchers at Paul Scherrer Institute propose a new therapy for lymphoma using radioimmunotherapy with terbium-161, which could target smaller tumours and increase survival rates. The isotope's conversion and Auger electrons allow for precise treatment of cancer cells in the bloodstream.
A study published in Redox Biology sheds light on the role of phosphoribosyl pyrophosphate synthetase (PRPS) enzymes in maintaining redox homeostasis in cancer cells. Researchers found that PRPS1 and PRPS2 work together to drive lymphoma growth, providing a potential target for novel therapies.
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards to tackle disparities in cancer care, racial and ethnic differences in pediatric Hodgkin lymphoma, and access barriers to high-quality surgical cancer care. The awards support innovative research aimed at improving health outcomes f...
A new DNA-based blood test using PhasED-Seq technology detects minimal residual disease (MRD) in B-cell malignancies, offering a powerful tool for early detection and monitoring treatment response. The assay demonstrates exceptional performance and high accuracy in detecting cancer cells in the bloodstream.
A study published in Leukemia reveals that histone deacetylase 1 (HDAC1) acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma, delaying or preventing tumour development. HDAC inhibitors, such as entinostat, show promise as additional treatment options.
Researchers identified two distinct epigenetic profiles in Burkitt Lymphoma, one associated with a favorable clinical course and the other with early relapse and shorter survival. This discovery has implications for treatment strategies and may lead to personalized medicine approaches.
A new strategy for treating B-cell lymphoma has shown promising results with a next-generation CAR T cell therapy that incorporates IL18. The treatment achieved high remission rates of 81% and complete remission in 52%, with some patients experiencing durable responses lasting two years or more.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
A recent study found significant elevated expression of AID enzyme in B cells during Plasmodium falciparum malaria, linking the parasite to the development of Burkitt lymphoma. Elevated AID levels were also observed in Kenyan children with uncomplicated malaria.
Dr Ari Melnick brings extensive experience to the institute, with a focus on precision medicine and haematological diseases. He aims to accelerate innovative treatments and enhance patient outcomes through strong partnerships with leading hospitals and research centres.
A survey by Roswell Park Comprehensive Cancer Center found that 65% of Americans are unfamiliar with CAR T-cell therapy, a personalized cancer treatment option. The therapy involves extracting and engineering immune cells to recognize and kill cancer cells, with promising results in treating blood cancers.
A retrospective study of 20 cases of pulmonary MALT lymphoma found characteristic HRCT features such as air bronchogram and bronchiectasis, predominantly in the left upper lobe. Pathologically, tumors exhibited monocytoid and centrocyte-like cells with minimal atypia and B-cell markers CD20 and CD3.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers from the University of Southern Denmark found that tattooed individuals are more frequently diagnosed with skin and lymphoma cancers compared to those without tattoos. The study suggests that chronic inflammation in the lymph nodes triggered by tattoo ink may lead to abnormal cell growth and an increased risk of cancer.
The new guidelines aim to reduce trauma and delays in cancer diagnosis and treatment during pregnancy. Led by Dr Georgia Mills and Dr Gisele Kidson-Gerber, the guidelines provide a practical guide for doctors, including recommendations for diagnosis, staging, imaging safety, therapy, and supportive care.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
Researchers found that a new chemotherapy regimen, eBEACOPDac, resulted in fewer and less severe side effects compared to the existing regimen, eBEACOPP. Patients treated with eBEACOPDac experienced improved fertility recovery and reduced hospital time, making it a potential game-changer for treating Hodgkin lymphoma.
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
A new study from Reichman University explores the impact of conflicting assessments on the FDA's role in regulating breast implants. The agency faces challenges in balancing the interests of the medical industry and public health, leading to underreporting and inconsistent enforcement of regulations.
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
Continuous Medicaid enrollment is associated with a lower rate of late-stage lymphoma diagnosis, but fewer than half of patients are continuously enrolled before diagnosis. The study found that continuous coverage was strongly linked to a lower likelihood of late-stage diagnosis, especially in young adults.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
The two-year progression-free survival rate was 92% on the N-AVD arm compared to 83% on the BV-AVD arm, with fewer side effects and lower mortality rates. The study's results support the use of nivolumab-AVD as a standard treatment for stage 3-4 classic Hodgkin lymphoma.
A new treatment approach using immunotherapy has shown promising results in treating advanced Hodgkin lymphoma, with a remarkable 92% survival rate. The innovative clinical trial, led by Wilmot Director Jonathan Friedberg, also minimizes long-term side effects and toxicities.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers found that type II innate lymphoid cells transform after a cancer patient receives stem cells from a donor, preventing an effective immune system rebuilding. This new understanding may lead to better strategies for enhancing immune system recovery post-transplantation.
Patients with mantle cell lymphoma are more vulnerable to other diseases and infections due to intensive chemotherapy and a weakened immune system. A large-scale national study found that MCL patients had twice as many infections as reference subjects, with common causes including influenza and urinary tract infections.
Patients with CLL and NHL who received frequent immunoglobulin G tests had fewer infections, required fewer antimicrobial medications, and higher blood levels of IgG. Increased IgG testing is associated with a lower risk of severe infections, suggesting that clear clinician guidance may save lives.
Dr Biola M Javierre has been awarded a prestigious grant to study the role of mutations in noncoding regions of the genome in diffuse large B-cell lymphoma (DLBCL). Her research aims to identify genes affected by these mutations and their potential therapeutic targets.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
Researchers at UC Davis have updated their guidelines on neutering popular dog breeds, finding major differences in joint disorders and cancers. The study emphasizes personalized decisions, considering breed, sex, and context, and provides a table with guidelines for all 40 studied breeds.
A recent study from Lund University suggests that tattoos may be a risk factor for cancer in the lymphatic system. Researchers found that individuals with tattoos had a 21% higher risk of developing lymphoma compared to those without tattoos.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers at Weill Cornell Medicine have identified mutations in the ARID1A gene that drive follicular lymphoma transformation into a more aggressive form. These mutations make patients highly susceptible to experimental BAF-inhibitor drugs, offering new hope for early intervention therapies.
A new AI model, called Lars, can accurately detect signs of lymph node cancer in 90% of cases, reducing workload for radiologists and increasing access to healthcare. The model was developed using a large dataset of over 17,000 images from 5,000 patients and is based on deep learning technology.
A recent study published in the Journal of Veterinary Medicine found no significant correlation between canine lymphoma and proximity to environmental toxins. Researchers used data from Morris Animal Foundation's Golden Retriever Lifetime Study to map dog home addresses to radon zones and fracking wells, but did not find a link.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A new study has identified protein expression patterns that can predict the progression of follicular lymphoma, an incurable type of cancer. By analyzing tumour samples from patients, researchers have found a correlation between specific proteins and disease transformation, enabling early detection of high-risk patients.
A Stanford Medicine-led study identified circulating tumor DNA as a predictor of disease recurrence and grouped Hodgkin lymphoma into two subgroups with distinct genetic changes. This discovery may lead to more effective treatments with reduced toxicity.
A phase 2 trial PrE0405 showed an 85% complete response rate in 33 patients over 60 with mantle cell lymphoma who received venetoclax combined with bendamustine and rituximab. The combination was generally well-tolerated, with gastrointestinal toxicities common.
Researchers have identified a common mutation in the transcription factor IRF4 that drives tumor cell development in Hodgkin's lymphoma. This mutation leads to the activation of disease-relevant genes, and blocking its effects could provide new therapeutic opportunities.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
A recent study by UTHealth Houston found that the offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects. The study examined 6,882 offspring ages 12 months and younger and found an increased risk of specific types of defects in the offspring of women with a history of cancer.
Researchers found a 55% reduction in lymphoma risk and a 40% overall reduction in blood cancer risk among bariatric surgery patients. Women with high blood sugar at the start of the study benefited most from the surgery.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
Research by the University of Southampton found that repeated COVID-19 vaccine doses increase immune response in blood cancer patients, generating higher-quality antibodies. Booster vaccinations are essential for maintaining protection against COVID-19 in immunocompromised individuals.
Research found that women treated for childhood Hodgkin lymphoma may experience declining fertility and longer wait times to become pregnant, but overall success rates are high. The majority of women in the study who had tried to become pregnant were successful, with some being able to conceive at a younger age.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers analyzed 23 pregnant women with relapsed/refractory lymphoma and found a 24% progression-free survival rate and an 83% overall survival rate. The study suggests that delays in treatment may allow cancer to progress, while initiating chemotherapy can harm the fetus.